Drug intelligence / Profile preview

il-15-stimulated allogeneic nk cells

Development stage: Unknown
Lead developer: Hospital General Universitario Gregorio Marañon
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

IL-15-stimulated allogeneic NK cells is an investigational adoptive cell therapy consisting of donor-derived natural killer (NK) cells (CD56+, CD3-) isolated from a haploidentical allogeneic donor. The production process involves a double immunomagnetic depletion and enrichment protocol to isolate the NK cells, followed by ex vivo stimulation with interleukin-15 (IL-15) for approximately 12 to 20 hours. This stimulation is intended to enhance the anti-leukemic activity, survival, and cytotoxicity of the NK cells. The therapy is primarily being evaluated for the treatment of high-risk acute myeloid leukemia (AML) in adult patients undergoing unmanipulated haploidentical allogeneic stem cell transplantation with post-transplant cyclophosphamide. The mechanism leverages the graft-versus-leukemia (GvL) effect, where the activated NK cells target and eliminate residual leukemic cells during immune reconstitution.

Other names: IL-15-stimulated donor NK cellsIL15-stimulated donor NK cellsIL 15-stimulated donor NK cellsIL-15-activated haploidentical NK cellsIL15-activated haploidentical NK cellsIL 15-activated haploidentical NK cellsCD56+ CD3- NK cells

Targets

IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)NKG2D (Natural killer group 2 member D receptor)

Beyond the preview

Go deeper on il-15-stimulated allogeneic nk cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on il-15-stimulated allogeneic nk cells.

Explore the full profile